A ‘wonky’ congressional report will be a pharma talking point in the drug pricing debate
Kaiser Family Foundation's Larry Levitt talks about what the CBO's report forecasts, and how the pharmaceutical industry may use the numbers.
Read The Story 
After a court let them off the hook, generic Zantac makers plan to seek legal expenses from consumers
Inside Pfizer’s labs, ‘variant hunters’ race to stay ahead of the pandemic’s next twist
More than two-thirds of Congress cashed a pharma campaign check in 2020, new STAT analysis shows
Safety-net hospitals take big markups on cancer drugs for commercially insured patients, study finds
All Coverage
advertisement
